Clinical Trials Logo

Oral Cavity Mucosal Melanoma clinical trials

View clinical trials related to Oral Cavity Mucosal Melanoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05111574 Recruiting - Mucosal Melanoma Clinical Trials

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Start date: August 11, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.